Next Article in Journal
Correction: Langeskov-Christensen, M., et al. Aerobic Capacity Is Not Associated with Most Cognitive Domains in Patients with Multiple Sclerosis—A Cross-Sectional Investigation. Journal of Clinical Medicine 2018, 7, 272
Previous Article in Journal
Implication of Ventricular Assist Devices in Extracorporeal Membranous Oxygenation Patients Listed for Heart Transplantation
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessArticle

Low-Dose Propranolol as Secondary Prophylaxis for Varix Bleeding Decreases Mortality and Rebleeding Rate in Patients with Tense Ascites

1
Department of Internal Medicine, Hanyang University School of Medicine, Seoul 04763, Korea
2
Department of Fusion Data Analytics, School of Industrial Management Engineering, Korea University, Seoul 02841, Korea
3
Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si 14103, Korea
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(5), 573; https://doi.org/10.3390/jcm8050573
Received: 11 March 2019 / Revised: 20 April 2019 / Accepted: 24 April 2019 / Published: 26 April 2019
(This article belongs to the Section Gastroenterology & Hepato-Pancreato-Biliary Medicine)
  |  
PDF [1095 KB, uploaded 26 April 2019]
  |     |  

Abstract

Background and Aim: The risk and benefit of non-selective propranolol in patients with tense ascites are controversial. This study aimed to investigate the effect of propranolol as secondary prophylaxis on varix rebleeding and overall mortality in patients with tense ascites. Methods: This study used a database of the Health Insurance Review and Assessment Service (HIRAS), which provides health insurance to 97.2% of the total population in Korea. A total of 80,071 patients first variceal bleeding as the first decompensated complication enrolled from 2007 to 2014. Results: There were 2274 patients with large-volume ascites prescribed propranolol as secondary prophylaxis after first varix bleeding. The average prescription dose of propranolol as secondary prophylaxis was 74 mg/day in patients with large-volume ascites. The mean duration of rebleeding was 22.8 months. Result of analysis showed that low-dose propranolol (40–120 mg/day) compared to inadequate propranolol dose (<40 mg/day) as secondary prophylaxis decreased overall mortality and varix rebleeding in patients with tense ascites. Conclusions: Low-dose propranolol (40–120 mg/day) as secondary prophylaxis for variceal re-bleeding decreased overall mortality and varix rebleeding recurrence in patients with tense ascites. View Full-Text
Keywords: propranolol; ascites; mortality propranolol; ascites; mortality
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Park, J.H.; Jun, D.W.; Choi, J.; Koh, D.H.; Yoon, J.H.; Lee, K.N.; Lee, H.L.; Lee, O.Y.; Yoon, B.C.; Choi, H.S. Low-Dose Propranolol as Secondary Prophylaxis for Varix Bleeding Decreases Mortality and Rebleeding Rate in Patients with Tense Ascites. J. Clin. Med. 2019, 8, 573.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top